What happened
Kevin Duffin of Eli Lilly presented data at ARDD on a tirzepatide trial, SURMOUNT-5, in patients aged about 50 to 80 with obesity. He said the 72-week study showed a 1.38-year rise in chronological age, with some epigenetic clocks falling below baseline and pace-of-aging clocks showing a reduction. He also said organ-specific clocks showed biological age decreases in several organs, and he presented only the tirzepatide results.
“I point those out specifically because we saw good clinical endpoints in those disease areas in our clinical trials” — Kevin Duffin
Plain-English summary written by an AI model from the Lifespan.io story; the quote is copied word for word from it.
The original
- Headline
- ARDD 2026: Traditional Biology to AI-Driven Breakthroughs
- From
- Lifespan.io (news report)
- Published
- Oct 27, 2026
One of the oldest and biggest longevity conferences moved this year across the Atlantic, from Copenhagen to Boston. The new location brought ARDD close to several important longevity hubs and might have contributed to this edition’s […]